| |

The Surprising Link Between Vitamin B12 and Cancer Treatment Outcomes

The Surprising Link Between Vitamin B12 and Cancer Treatment Outcomes

Mesothelioma treatment is an intricate field where even the tiniest factors can play a big role. Recently, scientists discovered something unexpected: a connection between vitamin B12 and how well certain cancer treatments work.

Vitamin B12 and Immune-Boosting Cancer Treatments

Let’s talk about cancer treatments that boost the immune system, often called immunotherapy. These treatments work by helping the body’s defenses fight cancer. But here’s the twist: scientists found that when people had too much vitamin B12 in their blood while getting this treatment, it didn’t work as well.

Imagine vitamin B12 as a helpful friend. Normally, it keeps our body healthy by supporting nerve and blood cells. But when it’s too much, it might interfere with the special immune-boosting treatments for cancer.

In a study looking at people with advanced cancer, scientists checked their vitamin B12 levels while they got different cancer treatments. They found that those who had too much B12 didn’t respond as well to the immune-boosting treatment compared to others.

It’s a bit like having too many cooks in the kitchen. Sometimes, when there are too many helpers, things don’t turn out as expected. Similarly, having too much of this vitamin might confuse the body’s immune system, making it harder for the cancer treatment to do its job.

The study looked at lots of factors in the patients’ blood and found that high vitamin B12 levels were linked to not-so-great outcomes for those getting immune-boosting treatments. It was like a clue for the scientists, suggesting that this vitamin might affect how well these treatments work.

But why does this happen? Scientists think it might be because vitamin B12 can influence how our immune system works. When there’s too much of it, it might throw things off balance, making it harder for the immune-boosting treatment to fight cancer cells.

Understanding Vitamin B12’s Impact on Cancer Immunotherapy

This discovery is like finding a puzzle piece that doesn’t quite fit. It’s exciting because now scientists can explore more about how vitamins and the immune system work together in fighting cancer. They want to figure out ways to help these treatments work better, even when vitamin B12 levels are high.

So, what’s next? More research! Scientists want to learn more about how vitamin B12 interacts with our immune system and the tiny creatures in our gut called the microbiome. By understanding this better, they hope to find ways to make these treatments more effective, even when vitamin B12 levels are too high.

In the end, this discovery is like a guide for scientists. It shows them a new path to explore in the fight against cancer. And who knows? This could be a step closer to making cancer treatments even better for everyone.

Remember, it’s like having the right balance in everything—whether it’s vitamins in your body or the teamwork between different treatments. That balance might just be the key to winning the fight against cancer.

Source:

Turgeman, Ilit, Anat Reiner Benaim, Stav Regev -Tsur, Shahar Turgeman, Mahmud Abu Amna, Omar Badran, and Gil Bar-Sela. “Too Much of a Good Thing: The Association of Elevated Vitamin B12 Levels and Outcomes in Patients With Cancer Treated With Immunotherapy.” Journal of Immunotherapy (Hagerstown, Md.: 1997), November 1, 2023. https://doi.org/10.1097/CJI.0000000000000493.

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…